NASDAQ:CLNN Clene (CLNN) Stock Price, News & Analysis → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free CLNN Stock Alerts $0.37 +0.02 (+5.69%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.34▼$0.4650-Day Range$0.31▼$0.4452-Week Range$0.25▼$1.09Volume1.38 million shsAverage Volume867,781 shsMarket Capitalization$47.75 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Clene alerts: Email Address Clene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,648.3% Upside$6.50 Price TargetShort InterestHealthy0.16% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$17,535 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.34) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.45 out of 5 starsMedical Sector356th out of 905 stocksPharmaceutical Preparations Industry164th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingClene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClene has only been the subject of 2 research reports in the past 90 days.Read more about Clene's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.16% of the outstanding shares of Clene have been sold short.Short Interest Ratio / Days to CoverClene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clene has recently decreased by 69.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldClene does not currently pay a dividend.Dividend GrowthClene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLNN. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 6 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat Follows8 people have added Clene to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,535.00 in company stock.Percentage Held by Insiders25.10% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.28% of the stock of Clene is held by institutions.Read more about Clene's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clene are expected to grow in the coming year, from ($0.34) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clene is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clene is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClene has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Clene's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressTime is Running Out - June 25th Deadline Approaching!If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About Clene Stock (NASDAQ:CLNN)Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Read More CLNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLNN Stock News HeadlinesMay 29, 2024 | americanbankingnews.comClene (NASDAQ:CLNN) Stock Rating Reaffirmed by HC WainwrightMay 28, 2024 | globenewswire.comClene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)May 24, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative DiseasesMay 23, 2024 | markets.businessinsider.comAnalyst Scoreboard: 6 Ratings For CleneMay 14, 2024 | finance.yahoo.comClene to Present at Upcoming May ConferencesMay 14, 2024 | globenewswire.comClene to Present at Upcoming May ConferencesMay 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)May 10, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation HighlightsMay 9, 2024 | finance.yahoo.comClene First Quarter 2024 Earnings: Misses ExpectationsMay 8, 2024 | finanznachrichten.deClene Inc.: Clene Reports First Quarter 2024 Financial Results and Recent Operating HighlightsMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Clene (CLNN)May 8, 2024 | investorplace.comCLNN Stock Earnings: Clene Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comClene Reports First Quarter 2024 Financial Results and Recent Operating HighlightsMay 1, 2024 | finance.yahoo.comIBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob EtheringtonApril 23, 2024 | finance.yahoo.comBullish Clene Insiders Loaded Up On US$9.58m Of StockApril 17, 2024 | benzinga.comThe Analyst Verdict: Clene In The Eyes Of 5 ExpertsApril 16, 2024 | msn.comClene stock rallies 52% post-market on MS drug dataApril 16, 2024 | globenewswire.comEvidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual MeetingMarch 27, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MSMarch 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 19, 2024 | finance.yahoo.comIBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob EtheringtonMarch 17, 2024 | morningstar.comClene Inc Ordinary SharesMarch 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clene Amid Positive ALS Drug Data and Market DynamicsMarch 15, 2024 | globenewswire.comClene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®March 13, 2024 | finanznachrichten.deClene Inc.: Clene Reports Full Year 2023 Financial Results and Recent Operating HighlightsSee More Headlines Receive CLNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CLNN CUSIPN/A CIK1822791 Webclene.com Phone801-676-9695FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,648.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,500,000.00 Net Margins-7,873.23% Pretax Margin-7,873.23% Return on Equity-224.28% Return on Assets-60.21% Debt Debt-to-Equity Ratio1.66 Current Ratio1.23 Quick Ratio1.22 Sales & Book Value Annual Sales$650,000.00 Price / Sales73.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book3.72Miscellaneous Outstanding Shares128,430,000Free Float96,197,000Market Cap$47.75 million OptionableOptionable Beta0.45 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Robert Etherington MBA (Age 57)CEO, President & Director Comp: $1.06MMr. Morgan R. Brown CPA (Age 56)M.B.A., Chief Financial Officer Comp: $584.88kMr. Mark G. Mortenson ESQ. (Age 66)Chief Science Officer Comp: $729.92kMr. Jerry Miraglia J.D.General Counsel & Corporate SecretaryMr. Michael T. HotchkinChief Development OfficerMs. Mary Anne McneilHead of Human ResourcesDr. Benjamin M. Greenberg M.D.M.H.S., Head of MedicalMore ExecutivesKey CompetitorsRenovaroNASDAQ:RENBInventivaNASDAQ:IVAGreenwich LifeSciencesNASDAQ:GLSILifecore BiomedicalNASDAQ:LFCRAbeona TherapeuticsNASDAQ:ABEOView All CompetitorsInsiders & InstitutionsCVI Holdings LLCSold 111,200 shares on 5/7/2024Ownership: 0.000%General Resonance LlcSold 13,000 sharesTotal: $5,460.00 ($0.42/share)General Resonance LlcSold 10,000 sharesTotal: $3,300.00 ($0.33/share)General Resonance LlcSold 22,500 sharesTotal: $8,775.00 ($0.39/share)David J MatlinBought 250,002 shares on 11/10/2023Total: $102,500.82 ($0.41/share)View All Insider TransactionsView All Institutional Transactions CLNN Stock Analysis - Frequently Asked Questions Should I buy or sell Clene stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLNN shares. View CLNN analyst ratings or view top-rated stocks. What is Clene's stock price target for 2024? 4 equities research analysts have issued 12 month price objectives for Clene's stock. Their CLNN share price targets range from $4.00 to $10.00. On average, they expect the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 1,648.3% from the stock's current price. View analysts price targets for CLNN or view top-rated stocks among Wall Street analysts. How have CLNN shares performed in 2024? Clene's stock was trading at $0.2966 at the start of the year. Since then, CLNN shares have increased by 25.4% and is now trading at $0.3718. View the best growth stocks for 2024 here. Are investors shorting Clene? Clene saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 209,000 shares, a drop of 69.0% from the April 30th total of 674,500 shares. Based on an average trading volume of 849,800 shares, the short-interest ratio is currently 0.2 days. View Clene's Short Interest. When is Clene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CLNN earnings forecast. How were Clene's earnings last quarter? Clene Inc. (NASDAQ:CLNN) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.09). The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.16 million. Clene had a negative net margin of 7,873.23% and a negative trailing twelve-month return on equity of 224.28%. Who are Clene's major shareholders? Clene's stock is owned by many different retail and institutional investors. Top institutional shareholders include CVI Holdings LLC (0.00%). Insiders that own company stock include Alison Mosca, David J Matlin, General Resonance Llc, John Henry Stevens, Jonathon Gay, Robert Dee Etherington and Robert Glanzman. View institutional ownership trends. How do I buy shares of Clene? Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLNN) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.